Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application
Abstract Background Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton’s jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does n...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-11-01
|
Series: | Stem Cell Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13287-019-1450-3 |
id |
doaj-82cb1a72ad484b5d8dc135eba8a01520 |
---|---|
record_format |
Article |
spelling |
doaj-82cb1a72ad484b5d8dc135eba8a015202020-11-29T12:04:50ZengBMCStem Cell Research & Therapy1757-65122019-11-0110111110.1186/s13287-019-1450-3Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical applicationRaquel Cabrera-Pérez0Marta Monguió-Tortajada1Ana Gámez-Valero2Raquel Rojas-Márquez3Francesc Enric Borràs4Santiago Roura5Joaquim Vives6Cell Therapy Service, Blood and Tissue Bank (BST)REMAR-IVECAT Group, Health Science Research Institute Germans Trias i Pujol (IGTP)REMAR-IVECAT Group, Health Science Research Institute Germans Trias i Pujol (IGTP)Cell Therapy Service, Blood and Tissue Bank (BST)REMAR-IVECAT Group, Health Science Research Institute Germans Trias i Pujol (IGTP)ICREC Research Program, Health Science Research Institute Germans Trias i Pujol (IGTP)Cell Therapy Service, Blood and Tissue Bank (BST)Abstract Background Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton’s jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does not raise major ethical concerns. However, the osteogenic capacity of human WJ-derived multipotent mesenchymal stromal cells (MSC) remains unclear. Methods Here, we compared the baseline osteogenic potential of MSC from WJ and BM cell sources by cytological staining, quantitative real-time PCR and proteomic analysis, and assessed chemical and biological strategies for priming undifferentiated WJ-MSC. Concretely, different inhibitors/activators of the TGFβ1-BMP2 signalling pathway as well as the secretome of differentiating BM-MSC were tested. Results Cytochemical staining as well as gene expression and proteomic analysis revealed that osteogenic commitment was poor in WJ-MSC. However, stimulation of the BMP2 pathway with BMP2 plus tanshinone IIA and the addition of extracellular vesicles or protein-enriched preparations from differentiating BM-MSC enhanced WJ-MSC osteogenesis. Furthermore, greater outcome was obtained with the use of conditioned media from differentiating BM-MSC. Conclusions Altogether, our results point to the use of master banks of WJ-MSC as a valuable alternative to BM-MSC for orthopaedic conditions.https://doi.org/10.1186/s13287-019-1450-3Mesenchymal stromal cellsBone marrowWharton’s jellyOsteogenic differentiationBone regeneration |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Raquel Cabrera-Pérez Marta Monguió-Tortajada Ana Gámez-Valero Raquel Rojas-Márquez Francesc Enric Borràs Santiago Roura Joaquim Vives |
spellingShingle |
Raquel Cabrera-Pérez Marta Monguió-Tortajada Ana Gámez-Valero Raquel Rojas-Márquez Francesc Enric Borràs Santiago Roura Joaquim Vives Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application Stem Cell Research & Therapy Mesenchymal stromal cells Bone marrow Wharton’s jelly Osteogenic differentiation Bone regeneration |
author_facet |
Raquel Cabrera-Pérez Marta Monguió-Tortajada Ana Gámez-Valero Raquel Rojas-Márquez Francesc Enric Borràs Santiago Roura Joaquim Vives |
author_sort |
Raquel Cabrera-Pérez |
title |
Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application |
title_short |
Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application |
title_full |
Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application |
title_fullStr |
Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application |
title_full_unstemmed |
Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application |
title_sort |
osteogenic commitment of wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application |
publisher |
BMC |
series |
Stem Cell Research & Therapy |
issn |
1757-6512 |
publishDate |
2019-11-01 |
description |
Abstract Background Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton’s jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does not raise major ethical concerns. However, the osteogenic capacity of human WJ-derived multipotent mesenchymal stromal cells (MSC) remains unclear. Methods Here, we compared the baseline osteogenic potential of MSC from WJ and BM cell sources by cytological staining, quantitative real-time PCR and proteomic analysis, and assessed chemical and biological strategies for priming undifferentiated WJ-MSC. Concretely, different inhibitors/activators of the TGFβ1-BMP2 signalling pathway as well as the secretome of differentiating BM-MSC were tested. Results Cytochemical staining as well as gene expression and proteomic analysis revealed that osteogenic commitment was poor in WJ-MSC. However, stimulation of the BMP2 pathway with BMP2 plus tanshinone IIA and the addition of extracellular vesicles or protein-enriched preparations from differentiating BM-MSC enhanced WJ-MSC osteogenesis. Furthermore, greater outcome was obtained with the use of conditioned media from differentiating BM-MSC. Conclusions Altogether, our results point to the use of master banks of WJ-MSC as a valuable alternative to BM-MSC for orthopaedic conditions. |
topic |
Mesenchymal stromal cells Bone marrow Wharton’s jelly Osteogenic differentiation Bone regeneration |
url |
https://doi.org/10.1186/s13287-019-1450-3 |
work_keys_str_mv |
AT raquelcabreraperez osteogeniccommitmentofwhartonsjellymesenchymalstromalcellsmechanismsandimplicationsforbioprocessdevelopmentandclinicalapplication AT martamonguiotortajada osteogeniccommitmentofwhartonsjellymesenchymalstromalcellsmechanismsandimplicationsforbioprocessdevelopmentandclinicalapplication AT anagamezvalero osteogeniccommitmentofwhartonsjellymesenchymalstromalcellsmechanismsandimplicationsforbioprocessdevelopmentandclinicalapplication AT raquelrojasmarquez osteogeniccommitmentofwhartonsjellymesenchymalstromalcellsmechanismsandimplicationsforbioprocessdevelopmentandclinicalapplication AT francescenricborras osteogeniccommitmentofwhartonsjellymesenchymalstromalcellsmechanismsandimplicationsforbioprocessdevelopmentandclinicalapplication AT santiagoroura osteogeniccommitmentofwhartonsjellymesenchymalstromalcellsmechanismsandimplicationsforbioprocessdevelopmentandclinicalapplication AT joaquimvives osteogeniccommitmentofwhartonsjellymesenchymalstromalcellsmechanismsandimplicationsforbioprocessdevelopmentandclinicalapplication |
_version_ |
1724412285355556864 |